Risk of Getting COVID-19 in People With Multiple Sclerosis
暂无分享,去创建一个
M. Filippi | G. Tedeschi | G. Comi | M. Trojano | P. Ragonese | R. Totaro | M. Battaglia | P. Cavalla | F. Patti | L. Moiola | M. Amato | A. Lugaresi | M. Ponzio | P. Sola | F. Granella | V. Brescia Morra | G. De Luca | D. Paolicelli | P. Iaffaldano | M. Petracca | P. Mosconi | G. Lucisano | L. Brambilla | V. Lepore | D. Ferraro | G. Lus | G. Maniscalco | M. Capobianco | S. Montepietra | S. Malucchi | Simona Toscano | A. Manni | M. Vianello | I. Pesci
[1] M. Sormani,et al. DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and France , 2021, Annals of clinical and translational neurology.
[2] C. Oreja-Guevara,et al. Risk and outcomes of COVID‐19 in patients with multiple sclerosis , 2021, European journal of neurology.
[3] E. Havrdová,et al. Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement , 2021, Journal of Neuroimmunology.
[4] M. Trojano,et al. A randomized study of natalizumab dosing regimens for relapsing–remitting multiple sclerosis , 2021, Multiple sclerosis.
[5] P. Levy,et al. Review of the COVID-19 Risk in Multiple Sclerosis , 2021, Journal of cellular immunology.
[6] R. D. Du Pasquier,et al. Recurrence of disease activity after fingolimod discontinuation in older patients previously stable on treatment. , 2021, Multiple sclerosis and related disorders.
[7] G. Cutter,et al. Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis , 2021, JAMA neurology.
[8] D. Centonze,et al. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies , 2021, CNS Drugs.
[9] M. Sormani,et al. Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis , 2021, Annals of neurology.
[10] M. Raponi,et al. The role of air conditioning in the diffusion of Sars-CoV-2 in indoor environments: A first computational fluid dynamic model, based on investigations performed at the Vatican State Children's hospital , 2020, Environmental Research.
[11] Jana K Dickter,et al. Nosocomial Infections: A History of Hospital-Acquired Infections. , 2020, Gastrointestinal endoscopy clinics of North America.
[12] H. Hartung,et al. Multiple sclerosis and COVID-19. , 2020, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.
[13] C. Louapre,et al. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. , 2020, JAMA neurology.
[14] J. Lechner-Scott,et al. The COVID-19 pandemic and the use of MS disease-modifying therapies , 2020, Multiple Sclerosis and Related Disorders.
[15] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[16] B. Sharrack,et al. Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab , 2019, Neurology: Neuroimmunology & Neuroinflammation.
[17] R. Kinkel,et al. Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis , 2019, Therapeutic advances in neurological disorders.
[18] Angelo Ghezzi,et al. The Italian multiple sclerosis register , 2018, Neurological Sciences.
[19] G. Pardo,et al. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations , 2017, Journal of Neurology.
[20] T. Plavina,et al. A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis , 2016, Journal of clinical pharmacology.
[21] F. Novelli,et al. Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months , 2016 .
[22] H. Hartung,et al. Disease-modifying therapies and infectious risks in multiple sclerosis , 2016, Nature Reviews Neurology.
[23] G. Giovannoni,et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis , 2011, Journal of Neurology, Neurosurgery & Psychiatry.
[24] Peter C Austin,et al. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study , 2007, Statistics in medicine.
[25] Elaine L. Zanutto,et al. Estimating causal effects of public health education campaigns using propensity score methodology , 2005 .
[26] Lori S. Parsons. Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques , 2001 .